Endocrinol Metab.  2025 Feb;40(1):112-124. 10.3803/EnM.2024.2164.

Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis

• Kamrul-Hasan A
• Alam MS
• Dutta D
• Sasikanth T
• Aalpona FTZ
• Nagendra L

• KMID: 2565259
• DOI: http://doi.org/10.3803/EnM.2024.2164

Abstract

Background
Data on the carcinogenic potential of tirzepatide from randomized controlled trials (RCTs) are limited. Furthermore, no meta-analysis has included all relevant RCTs to assess the cancer risk associated with tirzepatide.
Methods
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases. The primary outcome was the overall risk of any cancer, and secondary outcomes were the risks of specific types of cancer in the tirzepatide versus the control groups.
Results
Thirteen RCTs with 13,761 participants were analyzed. Over 26 to 72 weeks, the tirzepatide and pooled control groups had identical risks of any cancer (risk ratio, 0.78; 95% confidence interval, 0.53 to 1.16; P=0.22). The two groups had comparable cancer risks in patients with and without diabetes. In subgroup analyses, the risks were also similar in the tirzepatide versus placebo, insulin, and glucagon-like peptide-1 receptor agonist groups. The overall cancer risk was also comparable for different doses of tirzepatide compared to the control groups; only a 10-mg tirzepatide dose had a lower risk of any cancer than placebo. Furthermore, compared to the control groups (pooled or separately), tirzepatide did not increase the risk of any specific cancer types. Despite greater increments in serum calcitonin with 10- and 15-mg tirzepatide doses than with placebo, the included RCTs reported no cases of papillary thyroid carcinoma.
Conclusion
Tirzepatide use in RCTs over 26 to 72 weeks did not increase overall or specific cancer risk.

Keyword

Tirzepatide; Meta-analysis; Diabetes mellitus, type 2; Obesity; Neoplasms; Thyroid neoplasms; Pancreatic neoplasms

Figure

• 

  Fig. 1. Flowchart on study retrieval and inclusion in the meta-analysis.

• 

  Fig. 2. Forest plot highlighting the risk of any cancer in the tirzepatide versus pooled control groups. IV, intravenous; CI, confidence interval.

• 

Reference

1. Watts EL, Moore SC, Gunter MJ, Chatterjee N. Adiposity and cancer: meta-analysis, mechanisms, and future perspectives. medRxiv [Preprint]. 2024; Feb. 18. https://doi.org/10.1101/2024.02.16.24302944.

2. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015; 350:g7607.

3. Platts J. Insulin therapy and cancer risk in diabetes mellitus. Clin Med (Lond). 2010; 10:509–12.

4. Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y, et al. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. Cancer Med. 2018; 7:1070–80.

5. Dąbrowski M. Diabetes, antidiabetic medications and cancer risk in type 2 diabetes: focus on SGLT-2 inhibitors. Int J Mol Sci. 2021; 22:1680.

6. Dicembrini I, Nreu B, Montereggi C, Mannucci E, Monami M. Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Acta Diabetol. 2020; 57:689–96.

7. Dicembrini I, Nreu B, Mannucci E, Monami M. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2019; 21:1871–7.

8. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011; 141:150–6.

9. Bezin J, Gouverneur A, Penichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023; 46:384–90.

10. Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024; 7:e2421305.

11. U.S. Food and Drug Administration. New drug therapy approvals 2022: advancing health through innovation [Internet]. Silver Spring: FDA;2023. [cited 2025 Jan 6]. Available from: https://www.fda.gov/drugs/novel-drug-approvals-fda/new-drug-therapy-approvals-2022.

12. U.S. Food and Drug Administration. FDA news release: FDA approves new medication for chronic weight management [Internet]. Silver Spring: FDA;2023. [cited 2025 Jan 6]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management.

13. Permana H, Yanto TA, Hariyanto TI. Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. Diabetes Metab Syndr. 2022; 16:102640.

14. Dutta D, Kamrul-Hasan AB, Nagendra L, Bhattacharya S. Efficacy and safety of novel twincretin tirzepatide, a dual GIP/GLP-1 receptor agonist, as an anti-obesity medicine in individuals without diabetes: a systematic review and meta-analysis. touchREV Endocrinol. 2024; 20:72–80.

15. Samuel SM, Varghese E, Kubatka P, Busselberg D. Tirzepatide-friend or foe in diabetic cancer patients? Biomolecules. 2022; 12:1580.

16. Popovic DS, Patoulias D, Popovic LS, Karakasis P, Papanas N, Mantzoros CS. Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2024; 213:111758.

17. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 [Internet]. London: Cochrane Collaboration;2023. [cited 2025 Jan 6]. Available from: www.training.cochrane.org/handbook.

18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71.

19. Kamrul-Hasan AB, Alam MS, Talukder SK, Dutta D, Selim S. Efficacy and safety of omarigliptin, a novel once-weekly dipeptidyl peptidase-4 inhibitor, in type 2 diabetes mellitus: a systematic review and meta-analysis. Endocrinol Metab (Seoul). 2024; 39:109–26.

20. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 [Internet]. London: Cochrane Collaboration;2023. Chapter 8, Assessing risk of bias in a randomized trial [cited 2025 Jan 6]. Available from: https://training.cochrane.org/handbook/archive/v6.4/chapter-08.

21. Review Manager (RevMan) [Computer program] version 7.2.0 [Internet]. London: Cochrane Collaboration;2024. [cited 2025 Jan 6]. Available from: https://revman.cochrane.org.

22. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol Assess. 2000; 4:1–115.

23. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928.

24. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines. 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64:383–94.

25. Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018; 392:2180–93.

26. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387:205–16.

27. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023; 402:613–26.

28. Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023; 29:2909–18.

29. Zhao L, Cheng Z, Lu Y, Liu M, Chen H, Zhang M, et al. Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial. JAMA. 2024; 332:551–60.

30. Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022; 10:623–33.

31. Rosenstock J, Wysham C, Frias JP, Kaneko S, Lee CJ, Fernandez Lando L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021; 398:143–55.

32. Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021; 385:503–15.

33. Ludvik B, Giorgino F, Jodar E, Frias JP, Fernandez Lando L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021; 398:583–98.

34. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021; 398:1811–24.

35. Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022; 327:534–45.

36. Rosenstock J, Frias JP, Rodbard HW, Tofe S, Sears E, Huh R, et al. Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial. JAMA. 2023; 330:1631–40.

37. Gao L, Lee BW, Chawla M, Kim J, Huo L, Du L, et al. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med. 2023; 29:1500–10.

38. Korner M, Christ E, Wild D, Reubi JC. Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications. Front Endocrinol (Lausanne). 2012; 3:158.

39. Sen S, He Y, Koya D, Kanasaki K. Cancer biology in diabetes. J Diabetes Investig. 2014; 5:251–64.

40. Gasbjerg LS, Gabe MB, Hartmann B, Christensen MB, Knop FK, Holst JJ, et al. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides. 2018; 100:173–81.

41. Mortazavi M, Moosavi F, Martini M, Giovannetti E, Firuzi O. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. Crit Rev Oncol Hematol. 2022; 176:103749.

42. Vigneri PG, Tirro E, Pennisi MS, Massimino M, Stella S, Romano C, et al. The insulin/IGF system in colorectal cancer development and resistance to therapy. Front Oncol. 2015; 5:230.

43. Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010; 151:1473–86.

44. Thompson CA, Sturmer T. Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts. Diabetes Care. 2023; 46:249–51.

45. Look AHEAD Research Group, Yeh HC, Bantle JP, Cassidy-Begay M, Blackburn G, Bray GA, et al. Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the Look AHEAD randomized clinical trial. Obesity (Silver Spring). 2020; 28:1678–86.

46. Nagendra L, Bg H, Sharma M, Dutta D. Semaglutide and cancer: a systematic review and meta-analysis. Diabetes Metab Syndr. 2023; 17:102834.